The number of foreigners coming to China has increased significantly in the first quarter of this year as a result of the continued improvement in the country's policies to facilitate cross-border travel, the National Immigration Administration said on Tuesday.

Chinese President Xi Jinping arrived in Hanoi on Monday to pay a state visit to Vietnam.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business highlights.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024.

CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024.

BioMérieux announced Tuesday that its multiplex Biofire Spotfire Respiratory/Sore Throat Panel has received Health Canada approval.

Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China, with an incidence of 30.13–70.41/100000 population. The kidney is the most commonly involved organ in SLE, and 40% ~ 60% of SLE patients have lupus nephritis (LN).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.

Kidney dialysis firm Fresenius Medical Care said Monday that it is selling select laboratory assets to Quest Diagnostics.

The National Medical Products Administration (NMPA) has announced the priority review approval for Roche Diagnostics GmbH under its Priority Approval Procedure for Medical Devices (2016 No. 168).

Dutch diagnostics firm MRC Holland said this week that five of its blood-based tests for hereditary breast and ovarian cancer (HBOC) syndrome have received certification under Europe's In Vitro Diagnostic Regulation (IVDR).